Keith Suckling

Summary

Country: UK

Publications

  1. doi request reprint The ideal model in atherosclerosis and dyslipidaemia - does it exist?
    Keith Suckling
    291 Knightsfield, Welwyn Garden City, Hertfordshire, AL8 7NH, UK
    Expert Opin Drug Discov 1:507-11. 2006
  2. ncbi request reprint Discontinued drugs in 2005: cardiovascular drugs
    Keith Suckling
    291 Knightsfield, Welwyn Garden City, Herts AL8 7NH, UK
    Expert Opin Investig Drugs 15:1299-308. 2006
  3. ncbi request reprint Drug discovery in the metabolic syndrome: context and some recent developments
    Keith Suckling
    Expert Opin Ther Targets 11:801-8. 2007
  4. doi request reprint Phospholipase A2s: developing drug targets for atherosclerosis
    Keith Suckling
    GlaxoSmithKline, 291 Knightsfield, Welwyn Garden City, Hertfordshire AL8 7NH, UK
    Atherosclerosis 212:357-66. 2010
  5. doi request reprint The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity
    Keith Suckling
    Suckling Science Ltd, 291 Knightsfield, Welwyn Garden City, Herts, AL8 7NH, UK
    Expert Opin Ther Pat 22:199-204. 2012
  6. ncbi request reprint The continuing complexities of high-density lipoprotein metabolism in drug discovery and development
    Keith Suckling
    Expert Opin Ther Targets 11:1133-6. 2007
  7. doi request reprint The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe
    Keith Suckling
    Expert Opin Pharmacother 9:1067-70. 2008
  8. ncbi request reprint Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress
    Keith Suckling
    Expert Opin Investig Drugs 17:615-8. 2008

Detail Information

Publications8

  1. doi request reprint The ideal model in atherosclerosis and dyslipidaemia - does it exist?
    Keith Suckling
    291 Knightsfield, Welwyn Garden City, Hertfordshire, AL8 7NH, UK
    Expert Opin Drug Discov 1:507-11. 2006
    ....
  2. ncbi request reprint Discontinued drugs in 2005: cardiovascular drugs
    Keith Suckling
    291 Knightsfield, Welwyn Garden City, Herts AL8 7NH, UK
    Expert Opin Investig Drugs 15:1299-308. 2006
    ..Discontinued drugs in the atherosclerosis/dyslipidaemia area are discussed in more detail...
  3. ncbi request reprint Drug discovery in the metabolic syndrome: context and some recent developments
    Keith Suckling
    Expert Opin Ther Targets 11:801-8. 2007
    ..Finally, existing examples of drug targets for a range of biological mechanisms are considered, outlining their biology and points relevant to lead identification and optimisation and clinical development...
  4. doi request reprint Phospholipase A2s: developing drug targets for atherosclerosis
    Keith Suckling
    GlaxoSmithKline, 291 Knightsfield, Welwyn Garden City, Hertfordshire AL8 7NH, UK
    Atherosclerosis 212:357-66. 2010
    ..Note is taken of another phospholipase A2 (cytosolic) which has been less fully described but for which there has been some interest...
  5. doi request reprint The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity
    Keith Suckling
    Suckling Science Ltd, 291 Knightsfield, Welwyn Garden City, Herts, AL8 7NH, UK
    Expert Opin Ther Pat 22:199-204. 2012
    ....
  6. ncbi request reprint The continuing complexities of high-density lipoprotein metabolism in drug discovery and development
    Keith Suckling
    Expert Opin Ther Targets 11:1133-6. 2007
    ..This editorial commentary briefly discusses these and related issues from the perspective of 6 months following the termination of ILLUMINATE...
  7. doi request reprint The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe
    Keith Suckling
    Expert Opin Pharmacother 9:1067-70. 2008
    ..These results have surprised the field and led to a reassessment of the scientific and clinical basis for the overall mechanisms...
  8. ncbi request reprint Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress
    Keith Suckling
    Expert Opin Investig Drugs 17:615-8. 2008
    ..Whereas many new targets for drug discovery have been identified from new biology, such as that from the Human Genome Project, some targets have been known for decades but have not been exploited...